- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
FDA OKs Zeltiq device for treatment of fatty areas
The Food and Drug Administration has cleared Zeltiq Aesthetics’ CoolSculpting, a cryosurgical device, for the noninvasive spot reduction of fat in diet-resistant areas such as “love handles,” Medscape reports.
Pleasanton, Calif. - The Food and Drug Administration has cleared Zeltiq Aesthetics’ CoolSculpting, a cryosurgical device, for the noninvasive spot reduction of fat in diet-resistant areas such as “love handles,” Medscape reports.
According to a company statement, the device selectively targets subcutaneous fat cells with cold lipolysis, causing apoptosis and elimination to occur. Each one- to two-hour procedure yields a 20 percent reduction of fat in the treated area, with visible results within three weeks and the most dramatic results occurring over a two- to four-month period, the company states.
The device was previously cleared in the European Union and other global markets. The company says the device will be immediately available in select U.S. centers.
